Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

465
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
465
Trial and Error and Algorithm01:12

Trial and Error and Algorithm

411
A problem-solving strategy is a plan of action used to find a solution. Different strategies have distinct action plans. Trial and error involves trying different solutions until one works. For instance, to fix a broken printer, you might check ink levels, ensure the paper tray isn't jammed, and verify the printer's connection to your laptop. This method can be time-consuming but is commonly used. Thomas Edison, for example, used trial and error to find a suitable filament for the light...
411
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

370
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
370
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

265
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
265
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

349
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
349

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rivaroxaban and apixaban induce clotting factor Xa fibrinolytic activity.

Journal of thrombosis and haemostasis : JTH·2018
Same author

Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH.

Journal of thrombosis and haemostasis : JTH·2018
Same author

Risk stratification for the development of venous thromboembolism in hospitalized patients with cancer.

Journal of thrombosis and haemostasis : JTH·2018
Same author

Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study.

Journal of thrombosis and haemostasis : JTH·2018
Same author

Rapid quantitative D-dimer to exclude pulmonary embolism: a prospective cohort management study.

Journal of thrombosis and haemostasis : JTH·2015
Same author

Diagnosis and treatment of incidental venous thromboembolism in cancer patients: guidance from the SSC of the ISTH.

Journal of thrombosis and haemostasis : JTH·2015

Related Experiment Video

Updated: Feb 2, 2026

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models
04:40

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models

Published on: January 5, 2024

3.3K

Treatment algorithm in cancer-associated thrombosis: Canadian expert consensus.

M Carrier1, N Blais2, M Crowther3

  • 1Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON.

Current Oncology (Toronto, Ont.)
|November 23, 2018
PubMed
Summary

Managing blood clots in cancer patients requires careful consideration of bleeding risks. This consensus algorithm helps tailor anticoagulant therapy for venous thromboembolism (VTE) in cancer patients, balancing clot prevention with bleeding management.

Keywords:
Key Words Venous thromboembolismhemorrhageheparinlow-molecular-weightvenous thrombosis

More Related Videos

International Expert Consensus and Recommendations for Neonatal Pneumothorax Ultrasound Diagnosis and Ultrasound-guided Thoracentesis Procedure
05:50

International Expert Consensus and Recommendations for Neonatal Pneumothorax Ultrasound Diagnosis and Ultrasound-guided Thoracentesis Procedure

Published on: March 12, 2020

14.7K
Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus
06:15

Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus

Published on: March 6, 2019

52.0K

Related Experiment Videos

Last Updated: Feb 2, 2026

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models
04:40

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models

Published on: January 5, 2024

3.3K
International Expert Consensus and Recommendations for Neonatal Pneumothorax Ultrasound Diagnosis and Ultrasound-guided Thoracentesis Procedure
05:50

International Expert Consensus and Recommendations for Neonatal Pneumothorax Ultrasound Diagnosis and Ultrasound-guided Thoracentesis Procedure

Published on: March 12, 2020

14.7K
Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus
06:15

Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus

Published on: March 6, 2019

52.0K

Area of Science:

  • Oncology
  • Hematology
  • Clinical Medicine

Background:

  • Cancer patients face higher risks of recurrent venous thromboembolism (VTE) and major bleeding.
  • Individual cancer types and patient factors influence VTE and bleeding risks.
  • Current VTE management in cancer requires nuanced approaches due to these complexities.

Purpose of the Study:

  • To develop a consensus risk-stratification treatment algorithm for managing anticoagulant therapy in cancer patients with VTE.
  • To guide the tailoring of anticoagulant treatment for both acute and extended VTE management.
  • To optimize VTE prevention and minimize bleeding complications in this high-risk population.

Main Methods:

  • A committee of 10 Canadian clinical experts convened for a 1-day meeting.
  • A systematic literature review informed the development of a draft treatment algorithm.
  • The algorithm was refined using a web-based platform and online teleconferences.

Main Results:

  • A consensus risk-stratification treatment algorithm for VTE in cancer patients was developed.
  • The algorithm emphasizes considering bleeding risk, cancer type, and drug interactions.
  • It guides personalized anticoagulant treatment decisions for symptomatic and incidental VTE.

Conclusions:

  • The developed algorithm provides a framework for personalized anticoagulant therapy in cancer-associated thrombosis.
  • Clinicians should integrate bleeding risk, cancer specifics, drug interactions, and patient preferences.
  • Regular reassessment of anticoagulant therapy is crucial as cancer status evolves.